Ashvattha Therapeutics, Inc.

About

Ashvattha Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2015. The company specializes in developing novel nanomedicine therapeutics using its proprietary hydroxyl dendrimer (HD) platform technology, which is licensed from Johns Hopkins University. This technology allows for the selective targeting and reprogramming of activated cells in diseased tissues, particularly in areas of inflammation. The company is advancing its HD therapeutics (HDTs) across several therapeutic areas, including ocular neovascular diseases such as neovascular age-related macular degeneration and diabetic macular edema. It is also focused on neurology, specifically multiple sclerosis, and neuro-oncology, as well as addressing hyperinflammation related to conditions like COVID-19. Ashvattha has upcoming presentations scheduled to share data on its programs at various industry events in 2025. The leadership team includes Interim CEO Robert J. Dempsey and Chairman Jeffrey L. Cleland, along with a board comprising experts from various fields.